EyePoint, Inc. reported year-end 2025 results and advanced its lead asset Duravyu, a bioerodible intravitreal insert of the TKI vorolanib, through multiple late-stage milestones. Two identical phase 3 wet AMD trials (LUGANO and LUCIA; >900 patients) remain on track for topline data beginning mid-2026, while first patients have been dosed in the phase 3 DME program (COMO and CAPRI) with topline expected in the second half of 2027. The company strengthened launch preparation with the appointment of a chief commercial officer, completed registration manufacturing batches, extended U.S. IP on the insert formulation to 2043, and closed 2025 with $306 million in cash and investments—guiding runway into the fourth quarter of 2027.
The strategic question is whether a semiannual, sustained-delivery TKI can change the treatment cadence in retina care now dominated by long-interval biologics. EyePoint’s non-inferiority path versus on-label aflibercept—and a six-month redosing plan—aims squarely at reducing injection burden without sacrificing outcomes. If the label ultimately reflects durable disease control with minimal supplemental anti-VEGF use, Duravyu could redraw market dynamics in wet AMD and DME. If not, it risks becoming another incremental entrant in a category where efficacy bar and payer scrutiny have risen markedly.
The stakes are acute for patients and retina practices. Visit and injection burden remain the biggest friction points despite the success of Eylea HD and Vabysmo in extending dosing intervals to 12–16 weeks. A reliable six-month insert would decompress clinic schedules, expand capacity for a growing prevalence of diabetic eye disease, and improve adherence for patients struggling with frequent visits. For DME specifically, EyePoint is leaning into the inflammatory biology: newly analyzed preclinical data suggest vorolanib may modulate IL-6 signaling in addition to VEGF and PDGF. That hypothesis, if borne out clinically, could matter in a population where inflammation contributes to refractory edema. Conversely, TKIs carry a historical aura of ocular safety caution in the retina community; the DSMC’s “continue as planned” recommendation and consistent safety seen to date are necessary, but final adjudication will depend on phase 3 rescue rates, intraocular inflammation signals, and visual/anatomic durability across subgroups.
From a market access vantage point, the design choices are telling. On-label aflibercept control, six-month redosing, and a recognized non-inferiority framework set a pathway that payers understand. What they will demand are hard numbers on supplemental injections, visit reductions, and practice-level efficiencies that translate into total cost-of-care value under Medicare Part B buy-and-bill. Pricing latitude will hinge on demonstrable reductions in treatment burden versus Eylea HD and Vabysmo, as well as operational convenience compared with implants or refillable reservoirs. EyePoint’s completion of registration CMC batches and extended IP are clear signals it expects to defend a premium positioning if data cooperate.
The competitive backdrop is both cautionary and enabling. Prior sustained-delivery efforts—polymer depots, refillable devices, and antibody conjugates—have faced recalls, mixed efficacy, or safety surprises, driving many portfolios back to conventional biologics with longer intervals. That creates white space for a pharmacologic, office-based insert that can truly hit six months. Yet commercialization muscle matters: with minimal product revenue today and R&D driving a $232 million net loss in 2025, EyePoint’s early CCO hire suggests readiness to go it alone in wet AMD, even as DME readouts trail by a year. The logical inflection is mid-2026: will phase 3 data be strong enough on durability and safety to justify a solo launch—or to catalyze a late-stage partnership or acquisition from a company seeking a differentiated sustained-delivery beachhead in retina?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
